Skip to content

Fiber Intake in an End Stage Renal Disease (ESRD) Population Followed Over 2 Years

Fiber Content of Hemodialysis Patients' Diet and it's Cardiovascular Implications.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00874380
Enrollment
70
Registered
2009-04-02
Start date
2008-10-31
Completion date
2011-06-30
Last updated
2013-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Outcome, Kalemia Control, Lipid Profile

Keywords

Fiber, Dialysis, Renal Replacement Therapy, Food Frequency Questionnaire, FFQ, Dietary counseling

Brief summary

Our research involves the detailed description of the content of the diet of x dialysis patients. For our purpose we used a newly developed food frequency questionnaire. This is the first validated questionnaire specific for dialysis patients and we were the first to use it. Our special focus was the fiber content in the diet of our patient. Our thesis that they are way below the recommended guidelines for fiber intake was verified. Our follow will evaluate the effect of such at diet, mosTLy cardiovascular.

Interventions

OTHERIncreasing total fiber intake in patient's diet

Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.

Sponsors

Staten Island University Hospital
CollaboratorOTHER
Northwell Health
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with end stage renal disease on hemodialysis * Patients who are able to give informed consent

Exclusion criteria

* Pregnant women. * Cognitively impaired patients * PEG feeding

Design outcomes

Primary

MeasureTime frame
cardiovascular event2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026